VOXZOGO added 2.33 cm a year in Phase 3. Can BioMarin turn that growth signal into a new FDA indication?
BioMarin’s VOXZOGO met its Phase 3 hypochondroplasia endpoint with a 2.33 cm/year growth velocity benefit as an FDA filing moves forward.
Pharma & Biotech
Pharma & Biotech
Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?
Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.
Pharma & Biotech
Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data
VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.